These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 23951726)

  • 1. Evaluation of antibacterial activities of flomoxef against ESBL producing Enterobacteriaceae analyzed by Monte Carlo simulation.
    Ito A; Tatsumi YM; Wajima T; Nakamura R; Tsuji M
    Jpn J Antibiot; 2013 Apr; 66(2):71-86. PubMed ID: 23951726
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potent antibacterial activities of latamoxef (moxalactam) against ESBL producing Enterobacteriaceae analyzed by Monte Carlo simulation.
    Ito A; Tatsumi Y; Wajima T; Nakamura R; Tsuji M
    Jpn J Antibiot; 2014 Apr; 67(2):109-22. PubMed ID: 24956910
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics/Pharmacodynamics Evaluation of Flomoxef against Extended-Spectrum Beta-Lactamase-Producing Escherichia coli In Vitro and In Vivo in a Murine Thigh Infection Model.
    Tashiro S; Hayashi M; Takemura W; Igarashi Y; Liu X; Mizukami Y; Kojima N; Enoki Y; Taguchi K; Yokoyama Y; Nakamura T; Matsumoto K
    Pharm Res; 2021 Jan; 38(1):27-35. PubMed ID: 33404990
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Breakpoints for extended-spectrum beta-lactamase-producing Enterobacteriacae: pharmacokinetic/pharmacodynamic considerations.
    MacGowan A
    Clin Microbiol Infect; 2008 Jan; 14 Suppl 1():166-8. PubMed ID: 18154541
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Estimation of latamoxef (moxalactam) dosage regimens against β-lactamase-producing Enterobacterales in dogs: a pharmacokinetic and pharmacodynamic analysis using Monte Carlo simulation.
    Kusumoto M; Narita H; Motegi T; Harada K
    J Vet Med Sci; 2024 Aug; 86(8):841-846. PubMed ID: 38897952
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cefepime pharmacodynamics in patients with extended spectrum beta-lactamase (ESBL) and non-ESBL infections.
    Lee SY; Kuti JL; Nicolau DP
    J Infect; 2007 May; 54(5):463-8. PubMed ID: 17067681
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationship between the distribution of cefepime minimum inhibitory concentrations and detection of extended-spectrum β-lactamase production among clinically important Enterobacteriaceae isolates obtained from patients in intensive care units in Taiwan: results from the Surveillance of Multicenter Antimicrobial Resistance in Taiwan (SMART) in 2007.
    Jean SS; Lee WS; Bai KJ; Lam C; Hsu CW; Yu KW; Liao CH; Chang FY; Ko WC; Wu JJ; Chen YH; Chen YS; Liu JW; Lu MC; Liu CY; Chen RJ; Hsueh PR
    J Microbiol Immunol Infect; 2015 Feb; 48(1):85-91. PubMed ID: 23973410
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reevaluation of Enterobacteriaceae MIC/disk diffusion zone diameter regression scattergrams for 9 beta-lactams: adjustments of breakpoints for strains producing extended spectrum beta-lactamases.
    Jones RN; Craig WA; Ambrose PG; Dudley MN; Pottumarthy S
    Diagn Microbiol Infect Dis; 2005 Jul; 52(3):235-46. PubMed ID: 16105568
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of breakpoints of cephems for intraabdominal infections based on pharmacokinetics and pharmacodynamics in the peritoneal fluid of patients.
    Ikawa K; Morikawa N; Ikeda K; Ohge H; Sueda T
    J Infect Chemother; 2008 Apr; 14(2):141-6. PubMed ID: 18622678
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of infections with ESBL-producing organisms: pharmacokinetic and pharmacodynamic considerations.
    Andes D; Craig WA
    Clin Microbiol Infect; 2005 Nov; 11 Suppl 6():10-7. PubMed ID: 16209701
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro activity of flomoxef and comparators against Escherichia coli, Klebsiella pneumoniae and Proteus mirabilis producing extended-spectrum β-lactamases in China.
    Yang Q; Zhang H; Cheng J; Xu Z; Xu Y; Cao B; Kong H; Ni Y; Yu Y; Sun Z; Hu B; Huang W; Wang Y; Wu A; Feng X; Liao K; Shen D; Hu Z; Chu Y; Lu J; Su J; Gui B; Duan Q; Zhang S; Shao H
    Int J Antimicrob Agents; 2015 May; 45(5):485-90. PubMed ID: 25600890
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Determining a clinical framework for use of cefepime and β-lactam/β-lactamase inhibitors in the treatment of infections caused by extended-spectrum-β-lactamase-producing Enterobacteriaceae.
    Nguyen HM; Shier KL; Graber CJ
    J Antimicrob Chemother; 2014 Apr; 69(4):871-80. PubMed ID: 24265230
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of flomoxef in plasma, peritoneal fluid, peritoneum, and subcutaneous adipose tissue of patients undergoing lower gastrointestinal surgery: Dosing considerations based on site-specific pharmacodynamic target attainment.
    Hirano T; Ohge H; Ikawa K; Uegami S; Watadani Y; Shigemoto N; Yoshimura K; Kitagawa H; Kaiki Y; Morikawa N; Takahashi S
    J Infect Chemother; 2023 Feb; 29(2):186-192. PubMed ID: 36341996
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cefepime versus extended spectrum β-lactamase-producing Enterobacteriaceae.
    Nogueira Kda S; Daur AV; Reason IT; Gales AC; Costa LM
    Braz J Infect Dis; 2011; 15(2):167-9. PubMed ID: 21503406
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activity of chequerboard combinations of ceftaroline and NXL104 versus beta-lactamase-producing Enterobacteriaceae.
    Mushtaq S; Warner M; Williams G; Critchley I; Livermore DM
    J Antimicrob Chemother; 2010 Jul; 65(7):1428-32. PubMed ID: 20478991
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phenotypic detection of extended-spectrum beta-lactamase production in Enterobacteriaceae: review and bench guide.
    Drieux L; Brossier F; Sougakoff W; Jarlier V
    Clin Microbiol Infect; 2008 Jan; 14 Suppl 1():90-103. PubMed ID: 18154532
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacodynamic modeling of carbapenems and fluoroquinolones against bacteria that produce extended-spectrum beta-lactamases.
    Moczygemba LR; Frei CR; Burgess DS
    Clin Ther; 2004 Nov; 26(11):1800-7. PubMed ID: 15639692
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of the new VITEK 2 extended-spectrum beta-lactamase (ESBL) test for rapid detection of ESBL production in Enterobacteriaceae isolates.
    Spanu T; Sanguinetti M; Tumbarello M; D'Inzeo T; Fiori B; Posteraro B; Santangelo R; Cauda R; Fadda G
    J Clin Microbiol; 2006 Sep; 44(9):3257-62. PubMed ID: 16954257
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cefepime, piperacillin-tazobactam, and the inoculum effect in tests with extended-spectrum beta-lactamase-producing Enterobacteriaceae.
    Thomson KS; Moland ES
    Antimicrob Agents Chemother; 2001 Dec; 45(12):3548-54. PubMed ID: 11709338
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monte Carlo simulation for evaluation of the efficacy of carbapenems and new quinolones against ESBL-producing Escherichia coli.
    Nakamura T; Shimizu C; Kasahara M; Okuda K; Nakata C; Fujimoto H; Okura H; Komatsu M; Shimakawa K; Sueyoshi N; Ura T; Satoh K; Toyokawa M; Wada Y; Orita T; Kofuku T; Yamasaki K; Sakamoto M; Nishio H; Kinoshita S; Takahashi H
    J Infect Chemother; 2009 Feb; 15(1):13-7. PubMed ID: 19280294
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.